Moloney Securities Asset Management LLC trimmed its holdings in Precision BioSciences, Inc. (NASDAQ:DTIL – Free Report) by 9.2% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 49,199 shares of the company’s stock after selling 5,000 shares during the period. Moloney Securities Asset Management LLC’s holdings in Precision BioSciences were worth $479,000 at the end of the most recent quarter.
Separately, Janus Henderson Group PLC acquired a new stake in Precision BioSciences in the 1st quarter valued at approximately $7,739,000. Institutional investors own 37.99% of the company’s stock.
Precision BioSciences Price Performance
NASDAQ:DTIL opened at $10.88 on Friday. The firm has a market capitalization of $75.35 million, a PE ratio of -1.46 and a beta of 1.74. The business’s fifty day moving average price is $9.55 and its 200 day moving average price is $11.31. Precision BioSciences, Inc. has a 12 month low of $8.25 and a 12 month high of $19.43.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Precision BioSciences in a research note on Thursday, August 22nd.
Check Out Our Latest Analysis on Precision BioSciences
Precision BioSciences Profile
Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.
Featured Articles
- Five stocks we like better than Precision BioSciences
- 10 Best Airline Stocks to Buy
- Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- MarketBeat Week in Review – 8/26 – 8/30
- How is Compound Interest Calculated?
- Why Dell Can Continue Winning in AI and Beyond
Want to see what other hedge funds are holding DTIL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Precision BioSciences, Inc. (NASDAQ:DTIL – Free Report).
Receive News & Ratings for Precision BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.